DHDHREarnings Analysis财报电话会Source pending来源待核by InvestLog AIInvestLog AI 整理
Event time: 事件时间：
Published: 文章发布：
DHR earnings call: For the full year 2026, we are increasing our full year adjusted diluted net EPS guidance to $8.57-$8.62 versus our prior range of $8.45-$8.60. This reflects the benefit of our third quarter outperformance and represents double digit year-over-year EPS growth.丹纳赫公司 (DHR) 电话会：我们将2026年全年调整后摊薄每股净收益指引上调至8.57至8.62美元，此前指引区间为8.45至8.60美元。这反映了第三季度业绩超出预期的利好，并将实现两位数的同比每股收益增长。
Management remarks
Call period: 2026 Q3 · 2026-10-21
Guidance: Matt Gugino: For the full year 2026, we are increasing our full year adjusted diluted net EPS guidance to $8.57-$8.62 versus our prior range of $8.45-$8.60. This reflects the benefit of our third quarter outperformance and represents double digit year-over-year EPS growth.
Demand and orders: Matt Gugino: Respiratory revenue was approximately $350 million in the third quarter, down year-over-year, due primarily to lower global infection rates, but modestly ahead of our expectations as we saw customers purchase ahead of the upcoming respiratory season.
Margins: Matt Gugino: Additionally, we expect a fourth quarter adjusted operating profit margin of approximately 29.5%.
Analyst Q&A
Analyst Tycho Peterson asked: I have a lot of people asking why you are not accelerating here. Appreciate your comments on bioproduction a minute ago. You had the order resin delays, obviously, in biotech, that should come through. You do not have the China VBP headwind. You have recovering biotech, academic picking up a bit. So, why on earth would ex-respiratory be the same? Management Julie Sawyer Montgomery answered: As Matt discussed, we've delivered core growth ex respiratory in the 4%-5% range the last few quarters, so we think that's a reasonable starting point for 2027 based on the current end market conditions. I'm only a few weeks into the CEO role, but the time I spent with our teams and customers has certainly reinforced my confidence in our positioning and the improving end markets. We really want to work through our typical planning process here that we go through in Q4, then we will provide you a more quantitative outlook in January.
